Annals of Internal Medicine July 07, 2015

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy, Paul J. Pockros, Ziv Ben Ari, Yue Zhao, et al.

Bottom Line

In the phase 3 C-EDGE TN trial, a 12-week, all-oral, interferon- and ribavirin-free regimen of grazoprevir and elbasvir achieved a 95% sustained virologic response rate in treatment-naive patients with HCV genotype 1, 4, or 6, with a safety profile comparable to placebo.

Key Findings

1. Sustained virologic response at 12 weeks (SVR12) was achieved in 95% (299/316) of patients in the immediate-treatment group.

2. By genotype, SVR12 rates were 92% (144/157) for genotype 1a, 99% (129/131) for genotype 1b, 100% (18/18) for genotype 4, and 80% (8/10) for genotype 6.

3. Efficacy was maintained regardless of cirrhosis status, with SVR12 rates of 97% (68/70) in patients with compensated cirrhosis and 94% (231/246) in those without cirrhosis.

4. Virologic failure occurred in 4% (13/316) of patients (1 breakthrough infection, 12 relapses), which was highly associated with baseline NS5A resistance-associated polymorphisms in genotype 1a patients.

5. The regimen was exceptionally well-tolerated, with rates of serious adverse events identical between the active grazoprevir-elbasvir group (3%, 9/316) and the placebo group (3%, 3/105).

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

421

Patients

Duration

12 wk post-treatment

Median

Setting

Multinational, 60 centers

Population Treatment-naive adults with chronic HCV genotype 1, 4, or 6 infection, including patients with and without compensated cirrhosis.

Intervention Fixed-dose combination of oral grazoprevir 100 mg and elbasvir 50 mg once daily for 12 weeks.

Comparator Matched placebo once daily for 12 weeks (deferred treatment group).

Outcome Sustained virologic response 12 weeks after the completion of study therapy (SVR12), defined as unquantifiable HCV RNA.

Study Limitations

• The sample sizes for patients with HCV genotypes 4 and 6 were relatively small, limiting the statistical power for drawing definitive conclusions in these specific subgroups.

• The study excluded patients with decompensated cirrhosis and those with prior HCV treatment experience (these populations were evaluated in separate trials within the C-EDGE program).

• Patients with genotype 1a infection who possessed baseline NS5A polymorphisms had lower SVR12 rates, necessitating baseline resistance testing in clinical practice to determine the need for ribavirin or extended therapy duration.

Clinical Significance

The C-EDGE TN trial definitively demonstrated that the coformulated, once-daily single-tablet regimen of grazoprevir (an NS3/4A protease inhibitor) and elbasvir (an NS5A inhibitor) provides an overwhelmingly effective and well-tolerated cure for chronic HCV. Its excellent safety profile and robust efficacy across both cirrhotic and non-cirrhotic patients established it as a front-line direct-acting antiviral (DAA) therapy, significantly contributing to the clinical shift toward simplified, side-effect-free viral eradication strategies.

Historical Context

Historically, hepatitis C treatment relied heavily on pegylated interferon and ribavirin, which were plagued by severe adverse effects and sub-optimal cure rates. The advent of direct-acting antivirals (DAAs) revolutionized HCV management. First-generation DAAs improved efficacy but still required interferon. Grazoprevir and elbasvir represent the highly refined second wave of DAAs, allowing for completely oral, interferon-free, and ribavirin-free regimens. The landmark findings from the C-EDGE clinical program directly led to the FDA approval of Zepatier in 2016, providing a pivotal tool in the ongoing global public health effort to eradicate HCV.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the mechanisms of action of grazoprevir and elbasvir, and why is combination therapy utilized rather than monotherapy in the treatment of Hepatitis C?

Key Response

Grazoprevir is an NS3/4A protease inhibitor and elbasvir is an NS5A inhibitor. Combination therapy targets different steps of the viral life cycle simultaneously. This is essential to prevent the rapid emergence of resistance mutations, which occur easily due to the high error rate of the HCV RNA-dependent RNA polymerase.

Resident

Given the high efficacy and safety of the grazoprevir-elbasvir regimen, how does the absence of ribavirin and interferon alter the pre-treatment evaluation and adverse effect monitoring for a patient newly diagnosed with HCV?

Key Response

Interferon requires screening for psychiatric history and autoimmune disease, while ribavirin causes hemolytic anemia requiring intense CBC monitoring and is teratogenic. The DAA regimen removes these absolute contraindications and monitoring burdens, shifting the clinical focus toward baseline resistance testing and screening for drug-drug interactions.

Fellow

For patients with HCV genotype 1a treated with elbasvir/grazoprevir, how do baseline NS5A resistance-associated substitutions (RASs) impact the SVR12 rate, and how should this influence regimen modification?

Key Response

Baseline NS5A RASs at specific positions (e.g., 28, 30, 31, 93) significantly reduce the efficacy of elbasvir/grazoprevir in genotype 1a patients. Fellows must recognize that current practice requires baseline RAS testing for GT1a; if present, the regimen must be extended to 16 weeks and weight-based ribavirin added to maintain high SVR rates.

Attending

As DAAs like elbasvir/grazoprevir become a standard of care for HCV, what are the most critical drug-drug interaction pitfalls clinicians must anticipate, particularly regarding statins and antiretrovirals, when initiating this therapy in an aging, multimorbid population?

Key Response

Grazoprevir is an OATP1B1/3 inhibitor, which significantly increases statin levels (increasing myopathy and rhabdomyolysis risk), requiring statin dose reduction or suspension. Additionally, co-administration with strong CYP3A inducers (e.g., certain HIV PIs or efavirenz) is contraindicated. Meticulous medication reconciliation prior to initiating DAAs is paramount.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The C-EDGE TN trial utilized a double-blind, placebo-controlled design with a deferred treatment group. What are the ethical and methodological trade-offs of using a placebo control in a trial for a curable infectious disease when other effective DAA regimens were already entering the market?

Key Response

While a placebo group provides pristine safety and adverse event comparisons (proving the DAA has side effects comparable to placebo), assigning patients to placebo delays curative therapy. Methodologically, a non-inferiority design against an active comparator might be more ethically sound in a rapidly evolving landscape, though it requires a larger sample size and complicates the isolation of the drug's specific safety profile.

Journal Editor

How does collapsing cirrhotic and noncirrhotic patients, as well as multiple genotypes (1, 4, 6), into a single primary efficacy endpoint potentially mask clinically significant efficacy deficits in specific subgroups, and how should a reviewer interrogate the study's powering for these strata?

Key Response

While the overall SVR was 95%, aggregating easy-to-treat (noncirrhotic GT1b) with harder-to-treat populations can artificially inflate the perceived regimen robustness. A rigorous reviewer would demand sub-group power calculations and wide confidence interval disclosures to ensure smaller subgroups (e.g., GT6 or cirrhotics) truly achieved non-inferiority.

Guideline Committee

Based on the C-EDGE TN findings and subsequent real-world data, how do current AASLD/IDSA guidelines position elbasvir/grazoprevir for treatment-naive genotype 1b versus genotype 1a patients, and what specific baseline testing is mandated before recommendation?

Key Response

AASLD/IDSA guidelines recommend elbasvir/grazoprevir as a first-line option for treatment-naive GT1b patients for 12 weeks. However, for GT1a, guidelines give a strong recommendation to test for baseline NS5A RASs; if present, the recommendation shifts to extending therapy to 16 weeks with ribavirin, or choosing an alternative pan-genotypic regimen (like glecaprevir/pibrentasvir) to avoid the testing burden altogether.

Clinical Landscape

Noteworthy Related Trials

2014

ION-1 Trial

n = 865 · NEJM

Tested

Ledipasvir-sofosbuvir with or without ribavirin

Population

Treatment-naive patients with HCV genotype 1

Comparator

Ledipasvir-sofosbuvir alone vs with ribavirin

Endpoint

SVR12 (Sustained virologic response at 12 weeks)

Key result: Ledipasvir-sofosbuvir achieved SVR12 rates of 97 to 99 percent across all groups, proving high efficacy without the need for ribavirin.

2014

SAPPHIRE-I Trial

n = 631 · NEJM

Tested

Ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin

Population

Treatment-naive patients with HCV genotype 1 without cirrhosis

Comparator

Placebo

Endpoint

SVR12 (Sustained virologic response at 12 weeks)

Key result: The multi-targeted 3D DAA regimen plus ribavirin achieved an SVR12 rate of 96.2 percent, significantly superior to historical controls.

2015

ASTRAL-1 Trial

n = 740 · NEJM

Tested

Sofosbuvir-velpatasvir

Population

Patients with HCV genotypes 1, 2, 4, 5, or 6 (including those with compensated cirrhosis)

Comparator

Placebo

Endpoint

SVR12 (Sustained virologic response at 12 weeks)

Key result: SVR12 was achieved in 99 percent of patients receiving sofosbuvir-velpatasvir, showing remarkable pan-genotypic efficacy and safety.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis